What is Herantis Pharma Oyj (HRPMF)?

Herantis Pharma Oyj (HRPMF) is a stock in the Healthcare sector, Biotechnology industry. View full analysis on Stocks360.

What is the current price of HRPMF?

The current price of HRPMF is $3.51. Prices are updated in real time on Stocks360.

What is HRPMF's price-to-earnings (PE) ratio?

HRPMF's trailing twelve-month PE ratio is -13.06, based on current price and earnings per share data available on Stocks360.

What is HRPMF's market capitalization?

HRPMF's market capitalization is $59,465,016.00, placing it in the small-cap tier.

Herantis Pharma Oyj (HRPMF)

Stock analysis · OTC · Healthcare · Biotechnology

$3.51

Market Cap

$59.47M

PE (TTM)

-13.06

EPS (TTM)

N/A

Dividend Yield

0.00%

Beta

0.43

Day Range

$3.51 – $3.51

52-wk Range

$3.51 – $3.51

Avg Volume

N/A

Volume

1.10K

Herantis Pharma Oyj (HRPMF) is a publicly traded company in the Healthcare sector. Latest price: $3.51. Market cap $59.47M. Trailing PE -13.06. Sign in to Stocks360 for full DCF valuation, fundamentals, technicals, and AI-driven analysis.

Get full analysis → Short-Term Analysis →

Proprietary Signals

Signal snapshot temporarily unavailable.

About Herantis Pharma Oyj

Herantis Pharma Oyj, a biotechnology enterprise, specializes in creating disease-modifying therapies for Parkinson's disease (PD) that harness Cerebral Dopamine Neurotrophic Factor (CDNF). Central to its developmental efforts is HER-096, a sophisticated, compact, synthetic chemical peptidomimetic originating from the active parent molecule. This preclinical xCDNF candidate is currently being investigated for its therapeutic promise in PD and other neurodegenerative conditions. Additionally, the firm is advancing recombinant human Cerebral Dopamine Neurotrophic Factor (rhCDNF), a biological protein that is presently undergoing Phase I clinical evaluation in individuals afflicted with Parkinson's. Founded in 2008, Herantis Pharma Oyj maintains its corporate headquarters in Espoo, Finland.

Valuation

Trailing twelve months. Multiples relative to current market price.
P/E (TTM)	-13.06×
P/S (TTM)	0.00×
P/B	-260.03×
P/FCF (TTM)	-8.11×
EV / EBITDA	567.54×
EV / Sales	0.00×
Earnings Yield	-7.82%
Free Cash Flow Yield	-12.33%

Fundamentals

Trailing twelve months. Source: financial statements via market data.
Enterprise Value	$52.49M
Net Income (TTM)	-$4.15M
Free Cash Flow (TTM)	-$6.54M
Net Debt	-$605.00K
Working Capital	$1.94M
Gross Margin	0.00%
Operating Margin	0.00%
Net Margin	0.00%
Return on Equity	-220.33%
Return on Invested Capital	-258.81%